Bain Leads $300M Investment in Startup Built on Bristol Myers Immune Drugs

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five drugs that no longer fit its plans.

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)--Jul 28, 2025-

BMS and Bain Capital forge $300m immunology spinoff

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bristol Myers, Bain Capital form new company to develop immunology drugs

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Bristol Myers Squibb and Bain Capital Create New Company

PRINCETON, N.J. & BOSTON–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY, “BMS”) and Bain Capital today announced the creation of a new independent biopharmaceutical company (“NewCo”) focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital. Th…